| |
IN THIS ISSUE |
|
|
Bridging & Dawn
AC Forum
2007 15th User Group
USA User Group
Higher Risks of Stroke
New Drug for Leg & Lung Clots
|
 |
 |
Welcome to
the March edition of the DAWN AC Anticoagulation Software
E-Newsletter for 2007.
|
Bridging Therapy Soon To Be
Available Within DAWN AC |
|
|
|
|
 |
Low Molecular
Weight Heparin (LMWH) is used in Bridging and
Induction therapy (and occasionally to give added
protection for low INR's in Maintenance therapy).
Bridging refers to short term therapy aimed at
protecting the patient from potential thromboembolic
events while their oral anticoagulant is
deliberately reduced or stopped so the patient can
undergo a procedure. LMWH is used to "bridge" the
gap in their oral anticoagulant therapy. In
response to requests from a number of customers, 4S
is looking at ways to provide support for LMWH
dosing within Dawn AC.
We have already had some very
useful feedback from people regarding how we could
incorporate this functionality into Dawn
AC. However, we would be grateful for any more
feedback or ideas. Furthermore, if anybody carries
out Bridging therapy and would like to see our
discussion document please e-mail
sales@4s-dawn.com putting
Request for Dawn Bridging Document in the subject
heading.
|
|
AC Forum -
Chicago 3rd May - 5th May |
|
For those of you who are
attending the AC Forum in Chicago in May, we would be
 pleased
to meet you, during the reception and the breaks
throughout the conference, and show you our AC Software.
Also for those of you who
are interested in seeing the product and discussing its
features and benefits in more detail, we are holding a
short seminar on Friday 4th of May at the hotel which will
start at 6:00pm and finish around 7:30pm. We will also be
displaying a poster with DAWN AC Benchmarking in the USA.
Look forward to seeing
you there!
|
Dawn AC
Anticoagulation Software 15th User Group 2007 |
|
We have already received some of your
booking forms and therefore, would like to pre-warn people
that it is essential that we receive your forms as soon as
possible to save disappointment.
We are keen to hear from those of you
who would like to give a short talk at the User Group
Meeting, we are offering a ‘speaker’s package’ where there
will be a £100 reduction in the meeting fee and we
also help with your presentation preparation. In response
to user requests, we invite you to share how you use Dawn
AC in different settings eg laboratory based, community
based with POC, pharmacist managed. In addition, we would
be interested in your experiences with Version 7.
The User Group, as many of
you know, offers the chance for Health Care Professionals
to share ideas and learn alternative methods of best
practice within Anticoagulation therapy. As well as the
day being informative and beneficial, we try to make the
event enjoyable by providing an evening meal
and entertainment within the package price.
|
North American
User Group |
|
The North American User
Group is going to be held on the 12th October in Denver,
the day before the South West Symposium on Thrombosis and
Hemostasis, also being held in Denver, making
this, potentially, a very
informative and worthwhile trip.
We are, however, in need of
speakers to contribute to the success of the day. If
anyone would be interested in giving a short presentation,
rather like what is mentioned above, then again we would
be keen to hear from you.
|
Anti-Clotting
Drug Linked to Far Higher Stroke Rate |
|
 A
dramatic rise in the number of hemorrhagic strokes in
the US during the 1990s may be linked to increased use
of the anti-clotting drug warfarin.
A new study estimates the
rate of such strokes increased fivefold across the
decade, a period in which the distribution of warfarin
also soared. Researchers say that the findings should
make doctors more cautious about prescribing the
medication to those elderly patients at high risk of
hemorrhagic stroke.
A previous study revealed
that the rate of hemorrhagic stroke associated with the
drug increased from 0.8 cases per 100,000 people in 1988
to 4.4 per 100,000 in 1999. The rise in such cases was
particularly striking among patients aged 80 years and
above: this number leapt from 2.5 per 100,000 patients
to 45.9 per 100,000 over the same time period.
To read the full
article please follow this link:
http://www.newscientist.com/channel/health/dn10641-anticlotting-drug-linked-to-far-higher-stroke-rate.html
|
New Blood
Thinner For Patients With Leg & Lung Clots |
|
A new oral blood thinner
is being compared to Warfarin to see if it works as well
and is easier to manage long term.
An international study of
2,000 adult patients with these problems will determine if
 dabigatran,
manufactured by Boehringer Ingelheim, a Germany based
pharmaceutical company, makes long-term clot control
easier.
Previous work with
dabigatran indicates it could fit the bill. It works early
in the clotting process, inhibiting thrombin, one of the
main clotting factors. "When you cut yourself, platelets
start sticking, thrombin comes in and activates the whole
cascade of coagulation factors that form a clot. Warfarin
works later in the cascade, so getting something that
works earlier may be even better," says Dr. Gossage.
To read the full article
please follow this link:
http://www.medicalnewstoday.com/medicalnews.php?newsid=62931&nfid=crss |
